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Abstract: Introduction: Functional neuro-imaging with FDG PET CT in schizophrenic patients have reported certain 
patterns of increased or decreased metabolism in specific areas of the brain. Frontal lobe is one of the cortical areas 
consistently associated with schizophrenia and the activity levels have been reported to vary with the symptomatology at 
presentation. Predominantly positive symptoms cause and underlying hyperfrontality and negative symptoms are 
associated with hypofrontality. This study aims to assess the imaging patterns in unmedicated pediatric patients with a 
diagnosis of schizophrenia and predominantly positive symptoms. 
Patients and methods: 48 pediatric patients with a diagnosis of schizophrenia (all unmedicated, 38 never medicated) and 
10 healthy age-matched controls were evaluated with FDG PET CT. The patients met ICD-10 and DSM-IV criteria for 
schizophrenia and all reported psychotic, “positive” symptoms when tested.  
Results: Children with schizophrenia and positive symptoms had a pattern of diffuse hyper-metabolism involving the 
bilateral frontal cortices and could be demonstrated on quantification by region to occipital ratio comparison . Associated 
statistically significant differences were also found when comparing ratios of occipital to thalamic, striatal and temporal 
cortex in these patients when compared to controls.  
Conclusion: Diffuse frontal hypermetabolism or hyperfrontality is observed in children with schizophrenia when there is a 
predominance of positive symptoms. There could be a possible disruption of cortico-striato-thalamic feedback loops 
causing hyperfrontality as seen in in experimentally induced models of psychosis. 
Keywords: Hyperfrontality · FDG-PET, Pediatric, Schizophrenia, Frontal lobe, Thalamus, Positive symptoms. 
INTRODUCTION 
Various theories to elucidate the Etio-pathological 
basis of Schizophrenia have been increasingly 
discussed in the light of neuro-developmental or neuro-
degenerative pathways. Histological features correlated 
with clinical symptomatology points to some areas of 
the brain being affected more than the others. The 
prefrontal cortex, striatum, and thalamus form a neural 
circuit important in regulating sensory input, attention, 
and action. Deficits in these three areas in 
schizophrenia have been widely reported in both 
structural [1] and functional [2] brain imaging studies.  
However, it is possible that the metabolic pattern 
and underlying evolutionary abnormalities could be 
different in pediatric schizophrenic patients and could 
also vary depending on their clinical presentation, 
symptomatology and treatment status. The symptoms 
of schizophrenia fall into three broad categories: 
positive symptoms, negative symptoms and cognitive 
symptoms. Positive symptoms are psychotic behavior, 
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delusions or false beliefs ,thought disorders and 
movement disorders. The negative symptom 
constellation in schizophrenia includes psychomotor 
retardation, avolition, apathy, anhedonia, attentional 
impairment, and decreased emotional expression [3, 
4]. Negative symptoms are associated with poor 
premorbid function, the male sex, and a low IQ [5] and 
are correlated with poor outcome [6]. Functional 
imaging with Positron emission tomography (PET) and 
single photon emission computed tomography 
(SPECT), which measure regional cerebral blood flow 
(rCBF) and/or metabolism, reveal a number of 
abnormalities and deficiencies in persons with 
schizophrenia, compared with healthy subjects. One of 
the features which have been reported in multiple 
studies is a lower level of prefrontal cortical metabolism 
in schizophrenic subjects [7] which has also been 
confirmed by cognitive tests indicating frontal or pre-
frontal dysfunction, such as the Wisconsin Card Sorting 
Test [8-14] or others [15-17]. Thus hypofrontality has 
been related to negative symptomatology in 
schizophrenia [18] 
In the present study in a group of drug naïve or 
unmedicated pediatric patients with a diagnosis of 
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schizophrenia and predominantly “positive” 
symptomatology, we attempted to study the cerebral 
resting activity and metabolic pattern with FDG PET. 
Further attempt was made to examine other possible or 
consistent features such as frontal/pre-frontal 
dysfunction or involvement of other sub cortical 
structures like striatum and thalamus. 
METHODS 
Patient Characteristics 
The study was cleared by the Institutional review 
board and written informed consent was obtained from 
the primary care givers, who were parents in majority of 
the subjects. In case parents were considered 
incompetent to give consent, the same was obtained 
from their grand parents or immediate relatives who 
were responsible for the patient's care. 
Psychiatric rating evaluations were done 
independently by any two experienced clinicians with 
long experience in administering and interpreting the 
tests. Forty-eight patients (32 male, 16 female) who 
met the ICD-10 and DSM-IV criteria for schizophrenia 
were included in the study. Exclusion criteria included a 
diagnosis of mental retardation, any lifetime history of 
significant medical or neurological illnesses and 
substance use disorder. Information concerning socio-
demographic variables was collected from patients or 
from their parents/relatives. All patients were 
unmedicated and thirty-eight were totally drug naïve at 
the time of scanning. Mean age was 15.1 years (SD 
2.6), all but two were right handed. Mean duration of 
disorder since first onset was 18.6 (SD 11) months, 
age of onset 14.2 (SD 3.6) years; age at first 
hospitalization was 14.8 (3.8) years. Mean number of 
previous hospitalizations was 2.4 (SD 1.6). Mean level 
of education was 9.4 (SD 4.8) years. 
Psychopathology 
 Patients with schizophrenia, were scored with the 
Positive and Negative Syndrome Scale for 
Schizophrenia (PANSS). PANSS general score as 
rated by an experienced psychiatrist at baseline was 
40.2 (8.1), PANSS positive score 24.6 (SD3.2), PANSS 
negative score 20.8 (SD 7.9). The control group 
consisted of 10 age- and sex-matched healthy 
individuals, who were relatives of oncology patients 
referred to our department. They were also asked to 
give written informed consent and had no history of 
psychiatric or neurological diseases and were all-free 
of any medication. 
FDG-PET 
FDG-PET scanning was performed on a Siemens 
Symbia 6 PET CT scanner. The scanner acquires 63 
contiguous trans-axial planes, simultaneously covering 
15.5 cm of the axial field of view. Data acquisition 
follows a standardized protocol for regional acquisition 
of the brain, established at the Department of Nuclear 
Medicine. An intra-venous injection of 120 MBq (F-
18)FDG was given to each subject after over night 
fasting and checking of fasting blood sugar levels. This 
is followed by an uptake period of 30 to 45 minutes 
during which time the subject is placed in a dark room 
with no visual or auditory stimuli and encouraged to 
relax. The head of the subject is fixed in a head holder 
and adequately positioned in the gantry and then 
scanned with eyes closed in a moderately light 
environment. Acquisition starts with a diagnostic CT 
transmission scan used for subsequent attenuation 
correction. This is followed by the emission scan (3 
frames, 10 minutes/ frame, 128 x 128 matrix, 3D 
acquisition). Images were reconstructed by iterative 
reconstruction using OSEM and the images were 
corrected for scatter and attenuation. The data 
obtained from the reconstructed PET images was 
transferred to a work station with Scenium software 
(Siemens) which enables one to compare the patient 
data after stereotactic realignment to a 3-dimensional 
reference template created from a normal database of 
12 age matched patients. Deviations from the normal 
database may be assessed on the voxel-level 
evaluating statistical differences using the standard 
deviation criterion. This approach allows one to 
compare the baseline status in different individuals with 
a normal database as well as to assess the intra-
subject variation in repetitive studies on the same 
individual. Data from the set of 63 regions of interest 
(ROIs) covering the whole brain were pooled and 
combined to separate ROIs for frontal, parietal, 
temporal, occipital cortex as well as striatum, thalamus, 
cerebellum and brainstem. 
Statistics 
All statistics have been calculated using the SPSS 
software package. Ratios between different regions 
and the occipital cortex have been calculated to 
compensate for inter-individual variation of metabolic 
rates. Mean and standard deviation values have been 
calculated for the ratios to describe the distribution of 
the data. Student t tests were used to compare group 
differences between the patient group and the control 
group. 
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RESULTS 
Regional Metabolic Rates of Glucose 
The schizophrenic group had higher SUV values in 
almost all the quantified cerebral regions. However, the 
standard deviation for all areas were high in both the 
patient as well as control group and also in all the 
regions of the brain. None of the differences were 
statistically significant, suggesting high inter-individual 
variation. 
Thus, more attention should be paid to ratios 
between brain regions and the occipital cortex as 
reference, referred to as ‘metabolic ratios’. These also 
play an important role in diagnosing a frontal hypo- or 
hyper-metabolic pattern. Table 1 gives an overview of 
the calculated ratios as well as their standard deviation 
and also illustrates differences between the patient and 
the control group. 
The mean metabolic ratios of the patient population 
were higher than controls in all examined areas. 
The temporal -occipital ratios differed only slightly 
between the patients and control groups and was (0.97 
±0.04 vs. 0.94 ±0.07). Similarly the parietal-occipital 
ratios for the 2 groups were not significantly different 
(1.08±0.06 vs. 1.06 ±0.05). However, we found a 
significant difference of the frontal-occipital ratio 
(1.11±0.07 vs.1.0 3 ±0.06, p<0.05), which indicates a 
frontal hyper-metabolic pattern. Furthermore, 
statistically significant differences were found for the 
respective ratios for striatum (1.18 ±0.05 vs. 1.09 
±0.08) and thalamus (0.99 ±0.08 vs. 0.93 ±0.04). The 
mean frontal-occipital ratio in patients is 11.2 % higher 
than that in the control group. Among all examined 
metabolic ratios this ratio shows the strongest 
difference between patients and controls. 
Further attempt to look at any potential difference or 
asymmetrical influence between the two hemispheres 
revealed no significant difference in the metabolic 
ratios between patients and controls in the right 
hemisphere or left side. In addition, there were no 
significant difference between the metabolic ratios of 
any regions between the two hemispheres in each 
subject (Table 2). 
Table 1: Calculated Metabolic Ratios and Standard Deviations 
Patient group Control Group 
 
Mean    SD Mean   SD 
Frontal/occipital 1.11 0.07 1.03 0.06 
Parietal/occipital  1.08 0.06 1.06 0.05 
Temporal/occipital  0.97 0.04 0.94 0.07 
Thalamus/occipital 0.99 0.05 0.94 0.05 
Striatum/occipital 1.18 0.05 1.09 0.08 
 
Table 2: Calculated Metabolic Ratios for the Two Hemispheres in the Two Groups 
 Patients Controls 
 Mean    SD Mean    SD 
r/l ratio frontal  1.2 0.04 1.1 0.03 
r/l ratio parietal 1.06 0.05 1.03 0.06 
r/l ratio temporal 0.87 0.06 0.97 0.03 
r/l ratio occipital  1.11 0.04 1.09 0.06 
r/l ratio striatum  0.9 0.07 0.9 0.05 
r/l ratio thalamus  1.09 0.08 1.1 0.09 
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DISCUSSION 
This is a novel 18 F FDG PET-CT study exploring 
the metabolic pattern and possible differences between 
a group of pediatric patients diagnosed with 
Schizophrenia and having predominantly “positive “ 
symptomatology and an age matched control 
population. It is important to note that the subjects were 
not under any drug therapy or were totally drug naïve, 
as drug therapy would alter the underlying metabolic 
pattern. The study documents widespread cortical 
hypermetaboilism in the patient subgroup, with the 
most important and consistent feature being a relative 
frontal hypermetabolism or “hyperfrontality”. Though a 
consistent or statistically significant association was not 
found in many of the other cortical areas like parietal or 
mesial temporal regions, statistically significant relative 
hyper-metabolic pattern was noted in various other 
regions like thalamus, striatum and temporal lobes. All 
the patients except two were right dominant, though no 
significant right / left asymmetries could be 
demonstrated. The concept of frontal dysfunction, 
especially decreased activation or hypofrontality has 
been documented in schizophrenic patients, based on 
numerous functional and neuro-imaging studies, 
especially in patients with negative symptoms [19-21). 
In contrast, numerous reports also observe a 
relative hyperactive frontal cortex, termed 
hyperfrontality in animal models of ketamine or 
psylocybin induced psychosis [22-24]. Similarly, frontal 
hyperactivity has been documented in unmedicated 
schizophrenic patients presenting with acute episodes 
[25-30].  
Thus, we understand that there could be increased 
or decreased activation in various areas of the brain 
depending on the symptomatology, acuteness of 
presentation as well as treatment history. It is possible 
that patients prewsenting with negative symptoms 
could have more suppressed brain activity, specifically 
decreased frontal activity levels, as shown by 
Andreasen et al. [19]. This concept was further 
elucidated in another study, which found consistent 
patterns of hypo or hyper metabolism in various cortical 
areas in never treated schizophrenic patients [31] using 
SPECT data and r CBF depending on the symptom 
complex of presentation. A positive correlation was 
found between positive symptoms and increased rCBF 
in various regions including the frontal cortex. It has 
been postulated that a frontal hypermetabolism or 
increased activity could be due to the disruption of the 
cortico-striato-thalamic feedback loops, which inturn 
controls the thalamic filter function leading to high 
levels of sensory input [32] leading to a sensory 
overload of the frontal cortex and its limbic relay 
stations.  
It could be hypothesised that a pattern of reduced 
frontal and thalamic activation could be more 
associated with negative symptomatology in 
unmedicated schizophrenia patients while hyperactivity 
of these regions be observed more often in patients 
with more positive symptoms. However it is important 
to note that a similar pattern of frontal and thalamic 
dysfunction have also been described in acute 
psychosis of Bipolar etiology and alcohol hallucinosis, 
which closely resembles paranoid schizophrenia [33]. 
Thus this finding might not be specific for 
schizophrenia. It is illustrative to note that the 
observations and patterns in schizophrenic patients 
based on functional and neuro-imaging studies in 
schizophrenia have to be viewed and evaluated with 
caution as there a number of confounding variables 
which can affect findings, such as chronicity of 
symptoms, acuteness of the episode, drug history, 
patients’ psychopathology, imaging techniques, 
scanners and ambient status and stimulation of the 
patients at the time of scanning [34]. Multiple reports 
have demonstrated metabolic shift and realignment of 
imaging patterns in schizophrenic patients treated with 
typical or atypical neuroleptics, which demonstrate the 
importance of medication effects in neuro-imaging 
studies in schizophrenia. Reduction in frontal 
metabolism with attendant decrease in the metabolism 
of thalamus and striatum even with as single dose of 
the atypical neuroleptic risperidone has been 
documented [35-38].  
In the present study, we have tried to eliminate few 
of the confounding factors, by including mostly drug 
naïve subjects, with a short duration of onset of 
symptoms and predominantly positive symptoms alone. 
In addition, the study group is a fairly uniform pediatric 
population from a similar socio-economic, educational 
and geographical background. Thus, this study could 
serve as an indicator for the prognostication as well as 
to assess the progress in children with a diagnosis of 
schizophrenia. Consistent finding of hyperfrontality, in 
the absence of long duration of illness or drug therapy 
or prior history of neuro-psychiatric issues, underscores 
the potential role of the frontal lobe in patients with 
positive symptomatology. 
This study has to be viewed in the light of numerous 
limitations, few of which are the limited sample size and 
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lack of interventions with the addition of cognitive tasks 
which usually lead to an activation of the frontal lobe 
like the Wisconsin Card Sorting Test or others may 
have led to more significant results. It would be more 
meaningful to follow up these patients over time and 
medication or psychotherapy as the course and 
chronicity of the illnesses are typically varied. Younger 
patients with a small duration of illness should be 
further sub-classified on the basis of therapy response 
and functional improvement, which would be useful in 
studying the course of disease progression and control 
in different groups. 
To conclude, this study indicates a metabolic 
pattern of underlying cortical hypermetabolism in 
unmedicated pediatric schizophrenia with positive 
symptomatology, with significant activation of the 
frontal, striatal and thalamic areas.  
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